Home
overview

Personalised medicine is moving from science fiction to reality.

In Vitro Diagnostics currently represent an expanding market of around $30 billon – with Molecular Diagnostics represent a growing fraction of this market. Drugs developed with pharmacogenetic companion diagnostics hold a phenomenal potential to optimise treatments for patients and make enourmous profits for those who commercialise them.

As increasing understanding of genomics allows medical interventions to be tailored to the patient, SMi’s Molecular Diagnostics Conference will provide the perfect opportunity to keep abreast of developments. Both diagnostics companies and drug producers will benefit from hearing the latest thinking on diagnostic testing and pharmacogenetics.

With a panel of top industry experts, the conference will address a number of key areas including:

  • Developing companion diagnostics
  • Discovering and validating molecular biomarkers
  • Improving drug efficacy with personalised medicine
  • Using pharmacogenomics to increase drug safety
  • Market prospects and the health economics of diagnostics and personalised medicine
  • The regulatory regime for diagnostic tests

Confirmed speakers:

  • Eddie Blair, Managing Director, Integrated Medicines
  • Anil Modak, Associate Director, Medical Products Research and Development, Cambridge Isotope Laboratories
  • Glenn Miller, Vice President, General Manager, Genzyme
  • Ansar Jawaid, Statistical Genetics Group Leader, R&D Genetics, AstraZeneca
  • Daren Thorborn, HIV Project Leader, GlaxoSmithKline
  • David Johnston, Vice President and Chief Scientific Officer, Esoterix Clinical Trials Services
  • Angus Hastie, CEO, Human Genetic Signatures
  • David Huckle, Chief Executive, Adams Business Associates
  • Steven Wong, Professor of Pathology & Scientific Director, toxicology Department, Milwaukee County Examiners Office, Medical University of Wisconsin
  • Professor K.K. Jain, CEO, Jain PharmaBiotech
  • Eric Claas, Associate Professor, Department of Medical Microbiology, Leiden University Medical Centre
  • Fiona Rahman, Programme Manager - Clinical Diagnostics Healthcare EIA, Frost & Sullivan
  • Sian Astley, European Communications Manager, Norwich Bioscience Institutes & NuGO
  • Muireann Cohen, Research Associate, Imperial College London
  • Jorge Leon, CEO, Leomics Consulting

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

David Huckle

David Huckle, Chief Executive, Adams Business Associates

9:10 MOLECULAR DIAGNOSTICS - RESEARCH DEVELOPMENTS INTO CLINICAL PRACTICE

David Huckle

David Huckle, Chief Executive, Adams Business Associates

  • Application of Molecular Diagnostics in Life Science Research
  • Evolution of Uses for Pharmaceutical development
  • Evolution of Uses for Clinical Diagnostics
  • Evolution of Uses for Genetic Analysis
  • Market Quantification Comparisons for Molecular Diagnostics in Research, Drug Development and Clinical Diagnostics
  • 9:50 SAFETY AND EFFICACY BIOMARKERS - DRIVERS TO PERSONALISED HEALTHCARE

    Ansar Jawaid

    Ansar Jawaid, Statistical Genetics Group Leader, R&D Genetics, AstraZeneca

  • Challenges and opportunities of Personalised Healthcare
  • Experience with safety biomarkers
  • Experience with efficacy biomarkers
  • 10:30 Morning Coffee

    11:00 ONE SIZE FITS ONE – A PERSONALISED APPROACH TO HIV

    Daren Thorborn

    Daren Thorborn, HIV Project Leader, GlaxoSmithKline R&D

  • Observations and associations
  • Using screening technologies to reduce serious drug toxicities in the clinic
  • 11:40 COMMERCIALISATION OF A PHARMACOGENETIC COMPANION DIAGNOSTIC FOR AN ANTIRETROVIRAL

    Hawazin Faruki

    Hawazin Faruki, Vice President, LabCorp

  • Market research on pgx readiness
  • Evidence-based decisions on test utilization
  • Technical and regulatory factors
  • 12:20 Networking Lunch

    13:50 MARKET PROSPECTS FOR COMPANION DIAGNOSTICS AND PERSONALISED MEDICINE

    Dr. Fiona Rahman

    Dr. Fiona Rahman, Programme Leader - Clinical Diagnostics, Frost & Sullivan

  • Pharmacogenetics can give drugs that would have failed to gain approval another chance
  • But is explicitly limiting a drug’s potential market by personalisation ever really a good commercial idea?
  • Will personalised medicine mean the end of the era of ‘blockbusters’?
  • Strategies to achieve business success with companion diagnostics
  • Pricing and reimbursement opportunities for diagnostic tests and companion drugs
  • 14:30 MARKET OPPORTUNITIES IN NUTRIGENOMICS AND NUTRIGENETICS

    Siân Astley

    Siân Astley, European Communications Manager , Norwich BioScience Institutes (IFR & JIC) & NuGO

  • The latest work on genetic predispositions for obesity and heart disease
  • Developing diagnostic tests to aid prescribing nutraceuticals
  • The market for nutrigenomics
  • 15:10 Afternoon Tea

    16:20 THE USE OF PHARMACOGENETIC MARKERS FOR PERSONALISED JUSTICE

    Steven How Yan Wong

    Steven How Yan Wong, Professor of Pathology & Scientific Director, toxicology Department, Milwaukee County Examiners Office, Medical College of Wisconsin

  • PGx in understanding the possible contribution of genetics to side effect of drugs in Driving-under-the influence of drug cases in court in the future
  • 17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Angus Hastie

    Angus Hastie, CEO, Human Genetic Signatures

    9:10 A CONTINUUM OF CANCER CARE. MAKING Dx/Rx TRANSPARENT TO THE PATIENT

    Glenn Miller

    Glenn Miller, Vice President, General Manager, Genzyme Transgenics Corporation

  • Better disease characterization leads to better clinical decision making
  • Therapeutic selection, the role of the clinical laboratory
  • Therapeutic monitoring, moving beyond the subjective
  • Models of care that work for the patient
  • 9:50 MOLECULAR DIAGNOSTICS IN CLINICAL PRACTICE

    Eric Claas

    Eric Claas, Head of Molecular Diagnostics, Leiden Univ Medical Center

  • Replacing conventional diagnostic methods in routine microbiology
  • Improved diagnosis of infections by multiplexed molecular assays
  • When molecular test really make a difference for the patient
  • Reimbursement issues
  • Future development: where does it end
  • 10:30 Morning Coffee

    11:00 THE BIG MARKETS: MOLECULAR DIAGNOSTICS FOR MICROBIAL PATHOGENS

    Angus Hastie

    Angus Hastie, CEO, Human Genetic Signatures

  • Market Dynamics: Current Mol Dx Infectious Disease Detection Approaches
  • New Target Technology for a Platform-Agnostic, Single-Plex,Pan-Species Screen
  • Routine Practicalities: Demonstrating Clinical Performance and Instrument Readiness
  • The IP Minefield: Sticking to a Proprietary Path
  • Business Applications: Licensing, Assay Direct and Platform Strategies
  • 11:40 THE PERSPECTIVE OF THE NHS

    Rob Elles

    Rob Elles, Chairman, National Genetics Reference Lab, Manchester

  • Personalised medicine and reducing adverse drug reactions
  • Cost-benefit judgements made by the NHS
  • Recent NICE decisions on approval of companion diagnostics e.g. Herceptin
  • The guidelines for implementing molecular diagnostics into clinical practice
  • 12:20 Networking Lunch

    13:50 THE ROLE OF METABOLIC PROFILING IN BIOMEDICAL SCIENCES

    Muireann Coen

    Muireann Coen, Research Associate, Imperial College London

  • Analytical tools for metabolic profiling
  • Mathematical solutions for extracting biomarkers
  • Applications in animal models
  • Translation into man
  • Future perspevtives
  • 14:30 DIAGNOSTIC BREATH TEST IN PERSONALISED MEDICINE

    Anil Modak

    Anil Modak, Associate Director, Medical Products Research & Development, Cambridge Isotope Laboratories

  • Uracil-13C breath test to identify DPD/DPHD deficiency to personalize 5-FU therapy
  • Pantoprazole-13C breath test to identify CYP2C19 enzyme deficiency to personalize Helicobacter pylori eradication therapy
  • Dextromethorphan-13C breath test for evaluating CYP2D6 enzyme activity to personalize Tamoxifen therapy
  • Phenylalanine-13C breath test for monitoring liver regeneration in living human liver donor following transplant surgery
  • Sodium bicarbonate-13C breath test to monitor COPD patients suffering from hypercapnia
  • L-DOPA-13C breath test to personalize Parkinsons disease medication.
  • 15:10 Afternoon Tea

    15:40 THE MOLECULAR DIAGNOSTICS MARKET IN THE US

    Jorge Leon

    Jorge Leon, CEO, Leomics Consulting

  • Forecast of future diagnostics markets
  • Technological, economical and cultural barriers in the US
  • 16:20 ECONOMIC VALUE OF COMPANION DIAGNOSTICS FROM A PARTNERING PERSPECTIVE

    Eddie Blair

    Eddie Blair, Director, Integrated Medicines Ltd

  • Context of value modeling and assumptions used
  • Cash flows from modeling and extension to market value
  • Effects of risk adjustment and macroeconomic considerations
  • Case studies where such value modeling has credibility
  • 17:00 Chairman’s Closing Remarks and Close of Conference

    +

    VENUE

    The Hatton, at etc. venues

    51/53 Hatton Garden, London, United Kingdom

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.